NEW YORK, Dec. 15 Reportlinker.com announces that a new market research report is available in its catalogue:
Boehringer Ingelheim GmbH: PharmaVitae Profile
Advertisement
http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Advertisement
Reasons to Purchase
*Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector
*Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook
*Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Boehringer Ingelheim: PharmaVitae forecasts at a glance 8
Strategic insight 9
Leading position in core markets 9
Focused therapeutic coverage following key successes 9
Specialization can restrict opportunities 10
New launches struggle to match the decline of existing products 11
Drag on growth as historical drivers turn to decline 11
Decline highlights challenges beyond 2014 12
External product deals needed to extend growth 12
Historical reliance upon internal discoveries 12
Tougher competition for late-stage product deals 13
SWOT analysis 14
Strengths 14
Weaknesses 16
Opportunities 16
Threats 17
TABLE OF CONTENTS 19
TABLE OF FIGURES 21
Chapter 3 Quarterly news update 22
Key findings 22
Product developments 23
Deals and alliances 25
Product deals 25
Technology deals 26
M&A activity 26
Company announcements 27
Future product milestones 28
Chapter 4 Company introduction 29
Key findings 29
Background 30
M&A history 30
Current corporate structure 31
Prescription Pharmaceuticals 32
Consumer Health Care 33
Industrial Customer 33
Animal Health 34
Chapter 5 Company sales 35
Key findings 35
Prescription pharmaceutical sales and growth rate analysis, 2002-14 36
Product analysis 38
Product analysis, 2002-08 39
Product analysis, 2008-14 42
Therapy area analysis 47
Geographic analysis 51
Launch/core/expiry analysis 54
Explanation of launch/core/expiry analysis 54
Launch analysis, 2008-14 55
Core analysis, 2008-14 58
Expiry analysis, 2008-14 59
Generics analysis, 2008-14 61
Launch/core/expiry configuration, 2008-14 62
Molecule type analysis 64
Externalization analysis 67
Chapter 6 Company financials 70
Key findings 70
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 71
Operating costs and profit analysis 73
Operating costs and profit analysis, 2002-08 74
Operating cost ratio and profit margin analysis, 2002-08 75
Operating cost ratio and profit margin analysis, 2008-14 76
Operating costs and profit analysis, 2008-14 76
Chapter 7 Key products and competitors 77
Key findings 77
Overview 78
Respiratory 79
Spiriva franchise 79
Overview 79
Sales forecast 80
Success driven by unique market position 80
Spiriva's position strengthened by novel delivery device 81
Competing LAMAs delayed until 2012 in the US 82
Combination set to extend Spiriva franchise, but will not maintain growth 82
Cardiovascular 84
Micardis franchise 84
Overview 84
Sales forecast 85
Uptake driven by best in class attributes 85
Growth maintained despite competition across 2008-14 86
Lifecycle management strengthens franchise 86
Pradaxa 88
Overview 88
Sales forecast 89
Uptake driven by unmet need 89
Pradaxa may be adversely affected by DTI history 90
Competition will prevent greater capture of market share 90
Trial program designed to allow label expansion 91
Endocrine, metabolic & genetic disorders 92
Ondero (BI 1356) 92
Overview 92
Sales forecast 93
Expected to be the third DPP-IV inhibitor to market in the US 93
Central nervous system 94
Sifrol/ Mirapex 94
Overview 94
Sales forecast 95
Historically positioned as a market leading treatment for Parkinson's disease 95
Late entry to once-daily market limits sales potential 96
Genitourinary 97
Flomax 97
Overview 97
Sales forecast 98
Market leading BPH treatment 98
Generic erosion delayed by grant of pediatric exclusivity 99
Chapter 8 Appendix 100
R&D pipeline 100
References 101
Abbreviations 101
Exchange rates 103
About Datamonitor 104
About Datamonitor Healthcare 104
Datamonitor consulting 104
Disclaimer 106
LIST OF TABLES
Table 1: Boehringer Ingelheim - PharmaVitae forecasts at a glance 8
Table 2: Boehringer Ingelheim key product developments, Q1-Q3 2009 23
Table 3: Boehringer Ingelheim product deals and alliances, Q1-Q3 2009 25
Table 4: Boehringer Ingelheim technology deals and alliances, Q1-Q3 2009 26
Table 5: Boehringer Ingelheim M&A activity, Q1-Q3 2009 26
Table 6: Boehringer Ingelheim company announcements, Q1-Q3 2009 27
Table 7: Boehringer Ingelheim future product milestones, 2009-11 28
Table 8: Boehringer Ingelheim's major consumer health care products 33
Table 9: Boehringer Ingelheim product portfolio overview ($m), 2002-08 39
Table 10: Boehringer Ingelheim product portfolio overview ($m), 2008-14 42
Table 11: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2008-14 50
Table 12: Boehringer Ingelheim prescription pharmaceutical sales by geographic region ($m), 2008-14 53
Table 13: Boehringer Ingelheim launch portfolio overview ($m), 2008-14 55
Table 14: Boehringer Ingelheim core portfolio overview ($m), 2008-14 58
Table 15: Boehringer Ingelheim expiry portfolio overview ($m), 2008-14 59
Table 16: Boehringer Ingelheim generics portfolio overview ($m), 2008-14 61
Table 17: Boehringer Ingelheim prescription pharmaceutical sales by molecule type ($m), 2008-14 66
Table 18: Boehringer Ingelheim prescription pharmaceutical sales by source ($m), 2008-14 69
Table 19: Total Boehringer Ingelheim sales by business unit ($m), 2002-08 71
Table 20: Boehringer Ingelheim operating revenue/cost analysis ($m), 2002-08 74
Table 21: Boehringer Ingelheim operating cost ratio analysis (% of total revenues), 2002-08 75
Table 22: Key products overview 78
Table 23: Spiriva: overview 79
Table 24: Spiriva: sales forecast ($m), 2008-14 80
Table 25: Micardis: overview 84
Table 26: Micardis franchise: sales forecast ($m), 2008-14 85
Table 27: Pradaxa: overview 88
Table 28: Pradaxa: sales forecast ($m), 2008-14 89
Table 29: Ondero: overview 92
Table 30: Ondero: sales forecast ($m), 2008-14 93
Table 31: Sifrol: overview 94
Table 32: Sifrol franchise: sales forecast ($m), 2008-14 95
Table 33: Flomax: overview 97
Table 34: Flomax: sales forecast ($m), 2008-14 98
Table 35: Boehringer Ingelheim's R&D pipeline (Phase I-registration) 100
Table 36: Exchange rates, 2009 103
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Boehringer Ingelheim's financial performance ($m), 2002-14 7
Figure 4: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2002-14 9
Figure 5: Boehringer Ingelheim prescription pharmaceutical sales by product category ($m), 2002-14 11
Figure 6: Boehringer Ingelheim SWOT analysis 14
Figure 7: Boehringer Ingelheim, current corporate structure 31
Figure 8: Boehringer Ingelheim, corporate structure by total net sales ($m), 2002-08 32
Figure 9: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 36
Figure 10: Key product sales ($m), 2002-14 38
Figure 11: Boehringer Ingelheim key sales growth drivers and resistors ($m), 2002-08 40
Figure 12: Boehringer Ingelheim key sales growth drivers and resistors ($m), 2008-14 44
Figure 13: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2002-14 47
Figure 14: Boehringer Ingelheim prescription pharmaceutical sales by geographic region ($m), 2002-14 51
Figure 15: Boehringer Ingelheim launch/core/expiry configuration ($m), 2008-14 62
Figure 16: Boehringer Ingelheim prescription pharmaceutical sales by molecule type ($m), 2002-14 64
Figure 17: Boehringer Ingelheim prescription pharmaceutical sales by source ($m), 2002-14 67
Figure 18: Boehringer Ingelheim operating revenue/cost analysis ($m), 2002-08 73
To order this report:
Pharmaceutical Industry: Boehringer Ingelheim GmbH: PharmaVitae Profile
More Market Research Report
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
